Montana Healthcare Programs
Drug Prior Authorization Coverage Criteria

Kesimpta™ (ofatumamab)

Review Criteria

Member must meet all the following criteria:

- Subject to Preferred Drug List
- Member must be 18 years of age or older
- Must be written by or in consultation with a neurologist
  - If not written by or in consultation with a neurologist, copy of recent consult must be submitted
- Member must have a diagnosis of relapsing form of multiple sclerosis (MS):
  - Clinically isolated syndrome (CIS)
  - Relapsing-remitting MS (RRMS)
  - Secondary progressive MS (SPMS)
- Approval granted for 1 year

Limitations:

- Initial dosing: maximum dose of 20mg sub-q once weekly for 3 doses
- Maintenance dosing: maximum of 20mg sub-q every month starting week 4